SOURCE: The Bedford Report

The Bedford Report

January 04, 2011 11:25 ET

Drug Makers Appear Poised for Growth in 2011

The Bedford Report Provides Analyst Research on Avanir Pharmaceuticals & Warner Chilcott

NEW YORK, NY--(Marketwire - January 4, 2011) - Drug makers haven't been impervious to the economic downturn but they have endured better than most. This is partly due to the fact that demand for pharmaceuticals remains fairly constant even during recession. As 2011 kicks off there is plenty of optimism regarding the drug manufacturing sector as firmer pricing and new products have improved sales and earnings trends. Moreover -- similar to last year -- Merger and Acquisition activity is likely to play a large role throughout the sector. The Bedford Report examines the outlook for companies in the Drug Manufacturers - Others Industry and provides research reports on Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) and Warner Chilcott PLC (NASDAQ: WCRX). Access to the full company reports can be found at:

www.bedfordreport.com/2011-01-AVNR

www.bedfordreport.com/2011-01-WCRX

The healthcare industry research firm IMS Health projects an increase in worldwide growth in 2011. The firm forecasts 5% to 7% versus a pace of 4% to 5% in 2010. The firm has a meager growth outlook until at least 2015. 

Much of the growth is expected to come from emerging markets such as China, Brazil, India and South Korea. These countries are benefiting from increased government spending on health care and more extensive private health coverage for workers. IMS predicts sales growth of 15% in these markets.

The Bedford Report releases regular market updates on the Drug Manufacturers - Others Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

In recent industry news, the Obama administration pressed congress to revamp a research and development tax credit by increasing it by about 20 percent and make it permanent. The Pharmaceutical Research and Manufacturers of America, PhRMA, as well as the Advanced Medical Technology Association expressed support for the tax credit.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.bedfordreport.com/disclaimer

Contact Information